Literature DB >> 20580203

Antipsychotic drug side effects for persons with intellectual disability.

Johnny L Matson1, Sara Mahan.   

Abstract

Antipsychotic drugs are the most frequently prescribed of the psychotropic drugs among the intellectually disabled (ID) population. Given their widespread use, efforts to systematically assess and report side effects are warranted. Specific scaling methods such as the Matson Evaluation of Side Effects (MEDS), the Abnormal Inventory Movement Scale (AIMS), and Dyskinesia Identification System Condensed User Scale (DISCUS) are reviewed. Symptom patterns and a focus on additional research are discussed. While progress has been made, more and more systematic methods to research these problems are necessary.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20580203     DOI: 10.1016/j.ridd.2010.05.005

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  19 in total

Review 1.  Polypharmacy in the treatment of subjects with intellectual disability.

Authors:  Frank Häβler; Johannes Thome; Olaf Reis
Journal:  J Neural Transm (Vienna)       Date:  2014-05-25       Impact factor: 3.575

Review 2.  Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research.

Authors:  Maire O'Dwyer; Philip McCallion; Mary McCarron; Martin Henman
Journal:  Ther Adv Drug Saf       Date:  2018-06-20

3.  Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study.

Authors:  John A Tsiouris; Soh-Yule Kim; W Ted Brown; Jill Pettinger; Ira L Cohen
Journal:  J Autism Dev Disord       Date:  2013-03

Review 4.  Genetic Approaches to Understanding Psychiatric Disease.

Authors:  Jacob J Michaelson
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

5.  Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities.

Authors:  Kosuke Okazaki; Manabu Makinodan; Kazuhiko Yamamuro; Tomoyo Takata; Toshifumi Kishimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-14       Impact factor: 2.570

6.  Specialized psychiatric services: patient characteristics, referral practice and length of stay in a representative clinical sample 2010-2016.

Authors:  Trine Lise Bakken; Siv Helene Hoidal
Journal:  Int J Dev Disabil       Date:  2018-03-15

7.  Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study.

Authors:  Rory Sheehan; Angela Hassiotis; Kate Walters; David Osborn; André Strydom; Laura Horsfall
Journal:  BMJ       Date:  2015-09-01

8.  Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study.

Authors:  Máire O'Dwyer; Jure Peklar; Philip McCallion; Mary McCarron; Martin C Henman
Journal:  BMJ Open       Date:  2016-04-04       Impact factor: 2.692

9.  Risperidone Induced Pisa Syndrome in a Male Adolescent.

Authors:  Serkan Güneş; Özalp Ekinci; Meltem Çobanoğulları Direk; Veli Yıldırım; Çetin Okuyaz; Fevziye Toros
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-02-29       Impact factor: 2.582

Review 10.  Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis.

Authors:  Cheryl McQuire; Angela Hassiotis; Bronwyn Harrison; Stephen Pilling
Journal:  BMC Psychiatry       Date:  2015-11-26       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.